Nanotechnology for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/12/2035 |
| _version_ | 1797501575392919552 |
|---|---|
| author | Bo Yang Ge Li Jiaxin Liu Xiangyu Li Shixin Zhang Fengying Sun Wenhua Liu |
| author_facet | Bo Yang Ge Li Jiaxin Liu Xiangyu Li Shixin Zhang Fengying Sun Wenhua Liu |
| author_sort | Bo Yang |
| collection | DOAJ |
| description | Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD. |
| first_indexed | 2024-03-10T03:20:25Z |
| format | Article |
| id | doaj.art-646894ed37e04613ae2a5b6dc66e642d |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T03:20:25Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-646894ed37e04613ae2a5b6dc66e642d2023-11-23T10:05:00ZengMDPI AGPharmaceutics1999-49232021-11-011312203510.3390/pharmaceutics13122035Nanotechnology for Age-Related Macular DegenerationBo Yang0Ge Li1Jiaxin Liu2Xiangyu Li3Shixin Zhang4Fengying Sun5Wenhua Liu6Department of Anesthesiology, The Second Hospital of Jilin University, Changchun 130012, ChinaSchool of Life Sciences, Jilin University, Changchun 130012, ChinaSchool of Life Sciences, Jilin University, Changchun 130012, ChinaSchool of Life Sciences, Jilin University, Changchun 130012, ChinaSchool of Life Sciences, Jilin University, Changchun 130012, ChinaSchool of Life Sciences, Jilin University, Changchun 130012, ChinaDepartment of Anesthesiology, The Second Hospital of Jilin University, Changchun 130012, ChinaAge-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.https://www.mdpi.com/1999-4923/13/12/2035age-related macular degeneration (AMD)nano-drug delivery systemcyclodextrinCRISPR/Cas9adeno-associated virus (AAV)hyaluronic acid |
| spellingShingle | Bo Yang Ge Li Jiaxin Liu Xiangyu Li Shixin Zhang Fengying Sun Wenhua Liu Nanotechnology for Age-Related Macular Degeneration Pharmaceutics age-related macular degeneration (AMD) nano-drug delivery system cyclodextrin CRISPR/Cas9 adeno-associated virus (AAV) hyaluronic acid |
| title | Nanotechnology for Age-Related Macular Degeneration |
| title_full | Nanotechnology for Age-Related Macular Degeneration |
| title_fullStr | Nanotechnology for Age-Related Macular Degeneration |
| title_full_unstemmed | Nanotechnology for Age-Related Macular Degeneration |
| title_short | Nanotechnology for Age-Related Macular Degeneration |
| title_sort | nanotechnology for age related macular degeneration |
| topic | age-related macular degeneration (AMD) nano-drug delivery system cyclodextrin CRISPR/Cas9 adeno-associated virus (AAV) hyaluronic acid |
| url | https://www.mdpi.com/1999-4923/13/12/2035 |
| work_keys_str_mv | AT boyang nanotechnologyforagerelatedmaculardegeneration AT geli nanotechnologyforagerelatedmaculardegeneration AT jiaxinliu nanotechnologyforagerelatedmaculardegeneration AT xiangyuli nanotechnologyforagerelatedmaculardegeneration AT shixinzhang nanotechnologyforagerelatedmaculardegeneration AT fengyingsun nanotechnologyforagerelatedmaculardegeneration AT wenhualiu nanotechnologyforagerelatedmaculardegeneration |